NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) saw a downside of -24.88% to $3.10 after subtracting -$1.02 on Wednesday. The 5-day average trading volume is 130,783 shares of the company’s common stock. It has gained $4.23 in the past week. An average of 86,736 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 373,054.
NMTC’s 1-month performance is -13.08% or -$1.65 on its low of $3.05 reached on 10/13/21. The company’s shares have touched a 52-week low of $2.49 and high of $13.50, with the stock’s rally to the 52-week high happening on 02/08/21. YTD, NMTC has lost -12.53% or -$1.62. However, the current price is down -77.07%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Jun 24, 111 days have gone by since the last insider trading activity for NeuroOne Medical Technologies Corporation (NMTC). Christianson Mark (Business Development Director) most recently sold 600 shares at $6.30 per share on Jun 24. This transaction cost the insider $3,780. Business Development Director, Christianson Mark, sold 11,300 shares at a price of $6.74 on Jun 23.
NeuroOne Medical Technologies Corporation (NMTC) has a trailing price-to-earnings (P/E) ratio of 26.30 for the broader industry and 32.23 for the sector.NMTC stock has a beta of 0.71. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 24.96 while the price-to-book (PB) in the most recent quarter is 5.57.
NeuroOne Medical Technologies Corporation’s quick ratio for the recent quarter was 12.30, with the current ratio over the same period at 12.40 meaning that NMTC stock is able to fulfill its debt obligations. In terms of profitability, the gross margin trailing 12 months is 90.10%. The trailing 12-month EBITDA margin is -250.79%.
Net income and sales went up compared to those figures reported in the previous quarter. EBITDA for the quarter stood at more than -$3.02 million. NMTC stock balance sheet for the recent quarter shows that total liabilities totaled 0.95 million, with total debt at $0.27 million. Shareholders hold equity totaling $12.0 million
Let’s look briefly at NeuroOne Medical Technologies Corporation (NMTC) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 12 October was 26.51% to suggest the stock is trending oversold, with historical volatility in this time period at 152.81%.
The stock’s 5-day moving average is $3.87, reflecting a -23.39% or -$0.94 change from its current price. NMTC is currently trading -33.60% above its 20-day SMA, -53.92% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -36.60% and -34.45% respectively.
Stochastic %K and %D was 33.75% and 40.76% and the average true range (ATR) pointed at 0.41. The RSI (14) points at 32.93%, while the 14-day stochastic is at 2.59% with the period’s ATR at 0.44. The stock’s 9-day MACD Oscillator is pointing at -0.16 and -0.18 on the 14-day charts.